http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 15 Jul 2026 06:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html si-local-file:///var/storage/secattach/20260715/26770247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html Wed, 15 Jul 2026 06:06:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html si-local-file:///var/storage/secattach/20260715/26770247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html Wed, 15 Jul 2026 06:06:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html si-local-file:///var/storage/secattach/20260715/26770247.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26770247.html Wed, 15 Jul 2026 06:06:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MESABI+TRUST++++++++++++++For%3A+Jul+14/26768806.html si-local-file:///var/storage/secattach/20260714/26768806.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MESABI+TRUST++++++++++++++For%3A+Jul+14/26768806.html Tue, 14 Jul 2026 16:45:00 -0400 MSB O.02025836 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MESABI+TRUST++++++++++++++For%3A+Jul+14/26768806.html si-local-file:///var/storage/secattach/20260714/26768806.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++MESABI+TRUST++++++++++++++For%3A+Jul+14/26768806.html Tue, 14 Jul 2026 16:45:00 -0400 MSB O.02025836 http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Press+Releases/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html <p> NEW YORK--(BUSINESS WIRE)-- <i><b>Announcement of Mesabi Trust Distribution</b></i> </p><p> The Trustees of Mesabi Trust (NYSE: MSB) declared a distribution of five cents ($0.05) per Unit of Beneficial Interest (“Unit”), payable on August 20, 2026, to Mesabi Trust Unitholders of record at the close of business on July 30, 2026. This compares to a twelve cents ($0.12) per Unit distribution declared for the same period last year. </p><p> The Trustees’ announcement today of a five cents ($0.05) per Unit distribution, as compared to the twelve cents ($0.12) per Unit distribution announced by the Trust at the same time last year, reflects the http://www.streetinsider.com/Business+Wire/Mesabi+Trust+Press+Release/26768246.html Tue, 14 Jul 2026 16:05:00 -0400 A.29172825 MSB O.02025836 O.21867030 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html si-local-file:///var/storage/secattach/20260714/26764929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html Tue, 14 Jul 2026 07:55:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html si-local-file:///var/storage/secattach/20260714/26764929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html Tue, 14 Jul 2026 07:55:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html si-local-file:///var/storage/secattach/20260714/26764929.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++MESOBLAST+LTD+++++++++++++For%3A+Jul+14/26764929.html Tue, 14 Jul 2026 07:55:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html <p>Mesoblast Limited (Nasdaq: MESO; ASX: MSB) said it has enrolled and treated at least 300 patients in its MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.</p> <p>The trial's primary endpoint is designed to show a statistically significant difference in pain reduction at 12 months between rexlemestrocel-L and a sham control group. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-2027, after the last treated patient completes 12 months of follow-up.</p> <p>Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation from http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html Mon, 13 Jul 2026 20:35:57 -0400 MESO MSB O.01273089 http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html <p>Mesoblast Limited (Nasdaq: MESO; ASX: MSB) said it has enrolled and treated at least 300 patients in its MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.</p> <p>The trial's primary endpoint is designed to show a statistically significant difference in pain reduction at 12 months between rexlemestrocel-L and a sham control group. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-2027, after the last treated patient completes 12 months of follow-up.</p> <p>Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation from http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html Mon, 13 Jul 2026 20:35:57 -0400 MESO MSB O.01273089 http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html <p>Mesoblast Limited (Nasdaq: MESO; ASX: MSB) said it has enrolled and treated at least 300 patients in its MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain associated with degenerative disc disease.</p> <p>The trial's primary endpoint is designed to show a statistically significant difference in pain reduction at 12 months between rexlemestrocel-L and a sham control group. Secondary endpoints include improvements in function, quality of life, and cessation of pain medication, including opioids. Top-line results are expected in mid-2027, after the last treated patient completes 12 months of follow-up.</p> <p>Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy designation from http://www.streetinsider.com/FDA/Mesoblast+reaches+300-patient+enrollment+in+back+pain+Phase+3+trial/26763495.html Mon, 13 Jul 2026 20:35:57 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Press+Releases/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089 http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html <p align="justify">NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has achieved its target of at least 300 patients treated in the MSB-DR004 pivotal Phase 3 randomized controlled trial of rexlemestrocel-L for chronic low back pain (CLBP) associated with degenerative disc disease. The trial aims to confirm the durable pain reduction from a single intra-discal injection of rexlemestrocel-L seen in the earlier MSB-DR003 trial.</p> <p align="justify">Silviu Itescu, Chief Executive of Mesoblast, said: “Completing our target of treating at least 300 patients http://www.streetinsider.com/Globe+Newswire/Mesoblast+Achieves+Target+of+300+Treated+Patients+in+Pivotal+Phase+3+Trial+for+Chronic+Low+Back+Pain/26763494.html Mon, 13 Jul 2026 20:35:00 -0400 MESO MSB O.01273089